The Chemours Company $CC Shares Purchased by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Chemours by 10.5% during Q1, owning over 1.4 million shares valued at $19.47 million.
• Insider buying activity includes Damian Gumpel purchasing 7,822 shares and CEO Denise Dignam acquiring 4,068 shares, indicating confidence in the company's performance.
• Analyst price targets for Chemours vary, with Royal Bank of Canada increasing its target to $15, while Goldman Sachs lowered it to $14, reflecting mixed market expectations.

Charles Schwab Investment Management Inc. boosted its holdings in The Chemours Company (NYSE:CC - Free Report) by 10.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,438,732 shares of the specialty chemicals company's stock after acquiring an additional 136,460 shares during the period. Charles Schwab Investment Management Inc. owned about 0.96% of Chemours worth $19,466,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in CC. Vanguard Group Inc. lifted its holdings in shares of Chemours by 8.3% in the 1st quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock worth $223,069,000 after purchasing an additional 1,263,047 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Chemours by 23.8% in the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock valued at $73,907,000 after buying an additional 839,849 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Chemours by 44.6% during the fourth quarter. Millennium Management LLC now owns 2,507,262 shares of the specialty chemicals company's stock valued at $42,373,000 after acquiring an additional 773,537 shares during the period. Balyasny Asset Management L.P. grew its position in shares of Chemours by 90.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 935,031 shares of the specialty chemicals company's stock worth $15,802,000 after acquiring an additional 445,335 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Chemours by 116.3% during the first quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company's stock worth $10,041,000 after acquiring an additional 399,097 shares during the last quarter. 76.26% of the stock is owned by institutional investors.

Insider Activity

In other Chemours news, insider Damian Gumpel purchased 7,822 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was bought at an average cost of $9.95 per share, with a total value of $77,828.90. Following the acquisition, the insider owned 131,701 shares of the company's stock, valued at $1,310,424.95. The trade was a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the purchase, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 25,290 shares of company stock worth $250,437. 0.47% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CC. Royal Bank Of Canada lifted their price objective on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Thursday, July 3rd. Mizuho boosted their price objective on Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. Barclays lowered their target price on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 28th. The Goldman Sachs Group cut their target price on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Finally, Morgan Stanley decreased their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.38.

Chemours Price Performance

Shares of NYSE:CC opened at $14.1350 on Friday. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -5.05 and a beta of 1.61. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The Chemours Company has a 12 month low of $9.13 and a 12 month high of $22.38. The stock's 50 day moving average price is $12.81 and its 200 day moving average price is $12.98.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.12. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The company had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same period last year, the firm earned $0.38 EPS. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 15th will be given a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.5%. Chemours's payout ratio is -12.50%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.